Augmenting signaling through this pathway using specific TrkB agonists may thus prove to be beneficial in alleviating neurological deficits in CS patients harbouring SLC9A6 mutations, as hippocampal BDNF/TrkB signaling is likely to be similarly diminished in these individuals. The gene discussed is NTRK2; the disease is Cowden syndrome 1.